IncaCell

IncaCell is a biotechnology company focused on revolutionizing cell therapy through its proprietary In-vivo Cell Assembly (INCA) platform. The company's technology enables the direct engineering of therapeutic cells, such as CAR-T cells, within a patient's own body, eliminating the need for complex and costly ex vivo manufacturing. By utilizing a modular 'tag-and-target' approach, IncaCell aims to deliver genetic instructions to specific immune cells in situ, potentially increasing the accessibility and efficacy of treatments for oncology. The platform is designed to overcome the limitations of current cell therapies in treating solid tumors. Headquartered in South San Francisco, IncaCell leverages research originally developed at leading academic institutions to create a scalable, 'off-the-shelf' cell therapy solution.